Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

NCT05110170 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: LY01005
DRUG: ZOLADEX® 3.6 mg

Sponsor

Luye Pharma Group Ltd.